secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0001356576-25-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus announces FDA label update for Qelbree with new pharmacodynamic and lactation data
--------------------------------------------------------------------------------

- FDA approved updated Qelbree label including serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition data.
- New lactation data show transfer of viloxazine into breastmilk is low; relative infant dose ~1% of maternal dose.
- Qelbree is first ADHD treatment to receive labeling approval under 2019 FDA guidance on Clinical Lactation Studies.
- Label update applies to Qelbree (viloxazine extended-release capsules) for ADHD in patients 6 years and older.
- Company cites commitment to building evidence for Qelbree use in ADHD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000002/0001356576-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000002/supn-20250127.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer